PET/MR in recurrent glioblastoma patients treated with regorafenib: [ 18 F]FET and DWI-ADC for response assessment and survival prediction

• Published in: British journal of radiology 2022-01, Vol.95 (1129), p.20211018-20211018
• Main Authors: Lombardi, Giuseppe, Spimpolo, Alessandro, Berti, Sara, Campi, Cristina, Anglani, Maria Giulia, Simeone, Rossella, Evangelista, Laura, Causin, Francesco, Zorzi, Giovanni, Gorgoni, Giancarlo, Caccese, Mario, Padovan, Marta, Zagonel, Vittorina, Cecchin, Diego
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Agents - therapeutic use; Brain Neoplasms - diagnostic imaging; Brain Neoplasms - drug therapy; Diffusion Magnetic Resonance Imaging - methods; Female; Fluorodeoxyglucose F18; Glioblastoma - diagnostic imaging; Glioblastoma - drug therapy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local - diagnostic imaging; Neoplasm Recurrence, Local - drug therapy; Phenylurea Compounds - therapeutic use; Positron-Emission Tomography - methods; Pyridines - therapeutic use; Radiopharmaceuticals; Retrospective Studies; Survival Analysis
• ISSN: 0007-1285; 1748-880X
• DOI: 10.1259/bjr.20211018

The use of regorafenib in recurrent glioblastoma patients has been recently approved by the Italian Medicines Agency (AIFA) and added to the National Comprehensive Cancer Network (NCCN) 2020 guidelines as a preferred regimen. Given its complex effects at the molecular level, the most appropriate imaging tools to assess early response to treatment is still a matter of debate. Diffusion-weighted imaging and O-(2- F-fluoroethyl)-L-tyrosine positron emission tomography ([ F]FET PET) are promising methodologies providing additional information to the currently used RANO criteria. The aim of this study was to evaluate the variations in diffusion-weighted imaging/apparent diffusion coefficient (ADC) and [ F]FET PET-derived parameters in patients who underwent PET/MR at both baseline and after starting regorafenib. We retrospectively reviewed 16 consecutive GBM patients who underwent [ F]FET PET/MR before and after two cycles of regorafenib. Patients were sorted into stable (SD) or progressive disease (PD) categories in accordance with RANO criteria. We were also able to analyze four SD patients who underwent a third PET/MR after another four cycles of regorafenib. [ F]FET uptake greater than 1.6 times the mean background activity was used to define an area to be superimposed on an ADC map at baseline and after treatment. Several metrics were then derived and compared. Log-rank test was applied for overall survival analysis. Percentage difference in FET volumes correlates with the corresponding percentage difference in ADC ( = 0.54). Patients with a twofold increase in FET after regorafenib showed a significantly higher increase in ADC pathological volume than the remaining subjects ( = 0.0023). Kaplan-Meier analysis, performed to compare the performance in overall survival prediction, revealed that the percentage variations of FET- and ADC-derived metrics performed at least as well as RANO criteria ( = 0.02, = 0.024 and = 0.04 respectively) and in some cases even better. TBR Max and TBR mean are not able to accurately predict overall survival. In recurrent glioblastoma patients treated with regorafenib, [ F]FET and ADC metrics, are able to predict overall survival and being obtained from completely different measures as compared to RANO, could serve as semi-quantitative independent biomarkers of response to treatment. Simultaneous evaluation of [ F]FET and ADC metrics using PET/MR allows an early and reliable identification of response to treatment and predict ov